Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy.

Mol Pharm 2016 09 19;13(9):3164-75. Epub 2016 Aug 19.

Laboratory of Experimental and Molecular Neuroimaging, Molecular Imaging Program at Stanford (MIPS), and Bio-X Program, Stanford University School of Medicine , Stanford, California 94305-5427, United States.

Glioblastoma remains an aggressive brain malignancy with poor prognosis despite advances in multimodal therapy that include standard use of Temozolomide. MicroRNA-21 (miR-21) and microRNA-10b (miR-10b) are oncomiRs overexpressed in glioblastoma, promoting many aspects of cancer biology. We hypothesized that PLGA nanoparticles carrying antisense miR-21 (antimiR-21) and antisense miR-10b (antimiR-10b) might beneficially knockdown endogenous miR-21 and miR-10b function and reprogram cells prior to Temozolomide treatment. PLGA nanoparticles were effective in intracellular delivery of encapsulated oligonucleotides. Concentrations of delivered antimiR-21 and antimiR-10b were optimized and specifically tailored to copy numbers of intracellular endogenous microRNAs. Coinhibition of miR-21 and miR-10b significantly reduced the number of viable cells (by 24%; p < 0.01) and increased (2.9-fold) cell cycle arrest at G2/M phase upon Temozolomide treatment in U87 MG cells. Cell-tailored nanoparticle-assisted concurrent silencing of miR-21 and miR-10b prior to Temozolomide treatment is an effective molecular therapeutic strategy in cell culture, warranting the need for further studies prior to future in vivo "personalized" medicine applications.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.6b00388DOI Listing
September 2016
8 Reads

Publication Analysis

Top Keywords

temozolomide treatment
12
mir-21 mir-10b
12
antimir-21 antimir-10b
8
plga nanoparticles
8
prior temozolomide
8
mir-21
5
temozolomide
5
mir-10b
5
number viable
4
nanoparticles carrying
4
viable cells
4
cycle arrest
4
overexpressed glioblastoma
4
antisense mir-21
4
antisense mir-10b
4
mir-10b antimir-10b
4
antimir-21 antisense
4
mir-21 antimir-21
4
cells 24%
4
carrying antisense
4

Similar Publications